EVT Stock Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EVT from our risk checks.
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.76 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.11 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | 1.09% |
| 5 Year Change | 7.10% |
| Change since IPO | 654.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| EVT | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 0.03% |
| 1Y | 0% | -6.0% | -3.3% |
Return vs Industry: EVT exceeded the Swiss Life Sciences industry which returned -6% over the past year.
Return vs Market: EVT exceeded the Swiss Market which returned -3.3% over the past year.
Price Volatility
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 0% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: EVT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EVT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,061 | Mario Polywka | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.
Evotec SE Fundamentals Summary
| EVT fundamental statistics | |
|---|---|
| Market cap | CHF1.60b |
| Earnings (TTM) | -CHF82.03m |
| Revenue (TTM) | CHF763.90m |
2.1x
P/S Ratio-19.5x
P/E RatioIs EVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVT income statement (TTM) | |
|---|---|
| Revenue | €781.43m |
| Cost of Revenue | €606.38m |
| Gross Profit | €175.05m |
| Other Expenses | €258.96m |
| Earnings | -€83.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 22.40% |
| Net Profit Margin | -10.74% |
| Debt/Equity Ratio | 39.1% |
How did EVT perform over the long term?
See historical performance and comparison